MOGAD maintenance treatment is specialist, but the timing lesson is concrete. Early oral corticosteroids can reduce relapse risk, with the spreadsheet naming about 12.5 mg/day and a five-month practical target after a first attack before benefit attenuates.

Save the neuroscience funding report for policy-aware learning rather than immediate bedside action. It links proposed NIH reductions, the BRAIN Initiative funding cliff and prior authorisation burden to future neurological treatment access and research-supported care.

This is mainly for applicants rather than clinicians looking for bedside decisions. It still has a good human factors point: programme choices should include commute, support network, patient population and life outside work, not reputation alone.

Rising head CT use is not the same as better neuroimaging care. Use the trend data as an audit prompt: age, rural residence, race and regional pathways can all alter who receives emergency CT head imaging.

When clinic attention slips or irritation starts to colour the consultation, this quieter neurology piece is worth keeping for later. It is less about diagnosis than about deliberate listening, narrative medicine and the reminder that community practice can still hold teaching, scholarship and professional connection.

Headache after 55 is not background noise in a geriatric review. This paper mainly nudges clinicians to ask about disability, sleep, mood, cognition and adherence, because headache burden in older adults can erode independence long before anyone calls it severe.

The outlier today is a career piece, but it is still useful for trainees and early-career neurologists. It pushes back against all-or-nothing thinking about research, links patient and advocacy-group work to meaning, and names post-training worry as a real early-career trap.

This is the most future-facing listen today. It is less about current bedside decisions than about what amyloid blood tests or PET positivity in cognitively unimpaired people may mean for prevention trials, delayed cognitive impairment, and the coverage and access work needed before use widens.

When CSF testing is being planned for suspected leptomeningeal metastasis, the useful question is what answer the team actually needs. This episode separates cytology, circulating tumour cell assays, and cell-free DNA, and it is strongest on why a positive cell-free DNA result does not itself prove malignant cells in the CSF.

New migraine drugs often generate excitement before the evidence is ready. This update stays grounded: phase 2 data show dose-responsive gains in pain and associated symptoms, but paraesthesias and feeling warm increase with dose, and routine use still waits for confirmatory trials.